40 results about "Oral suspensions" patented technology

An oral suspension pharmaceutical composition is disclosed for water soluble salts of arylalkanoic acid (NSAID) drugs such as ibuprofen and naproxen. When mixed with glyceryl esters such as glyceryl caprate / caprylate and water, the resulting combination forms a “liquid scaffold” structure that reliably enables the suspension of significant quantities of said arylalkanoic acid drugs. For example, suspensions containing 25% w / w arylalkanoic acid may be obtained using the aforementioned combination. Suspensions comprising further pharmaceutically active agents, in addition to said arylalkanoic acids, may also be prepared. Also disclosed is a binary blend of glyceryl caprate / caprylate and the sodium salt of ibuprofen and a ternary blend of glyceryl caprate / caprylate and the potassium salt of ibuprofen.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

The present invention relates to the field of pharmaceutical preparations, and in particular, to a sevelamer carbonate dry suspension and a preparation method thereof. In the sevelamer carbonate dry suspension, the dosage of the suspending agent is 0.13 - 0.33% of the total mass, the dosage of the flocculant is 0.05 - 0.39% of the total mass, the dosage of lactulose is 72.53 - 86.90% of the total mass, the dosage of the flavoring agent is 0.34 - 0.72% of the total mass, and the dosage of the sevelamer carbonate crude drug is 12.51 - 26.20% of the total mass. This sevelamer carbonate dry suspension not only has excellent dispersibility, but also can improve its gastrointestinal side effects.

The present disclosure provides novel methods and compositions for the use of Mariobavir in the treatment of pediatric and teenager patient populations. The present disclosure also provides compositions of Maripasvir in powder form for oral suspensions, which are useful in patients who are difficult to swallow pills, including pediatric and teenager patient populations.

The present invention provides a liquid composition comprising effective amount of Hydroxyurea for oral administration. The invention further discloses liquid formulation in form of ready to use oral suspension which remains stable at room temperature at the time of dispensing, storage and even after reopening of the container comprising the suspension. Also provided is a method of preparing the formulation and treating sickle cell anemia in pediatric patients.

A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.

An oral formulation of granules of an active ingredient such as gepotidacin or a pharmaceutically acceptable salt thereof that rapidly disperses in water, or an oral formulation comprising such granules. Such granules provide an oral suspension with good mouthfeel and palatability. This oral suspension is particularly useful for pediatric patient populations or patient populations with difficulty swallowing.

An oral formulation of, or comprising, granules of active pharmaceutical ingredient(s), such as gepotidacin or a pharmaceutically acceptable salt thereof, which disperse rapidly in water are presented. The granules generate a palatable oral suspension in solution with good mouthfeel and are particularly useful for the paediatric or hard-of-swallowing patient population.

The present invention discloses a sodium zirconium cyclosilicate oral suspension and a preparation method thereof, which comprise the following components in mass percentages: 10-30% of sodium zirconium cyclosilicate, 0.1-2.0% of cellulose, 0.01-0.30% of suspending agent, 0-10% of flavoring agent, 0-1.0% of preservative, and purified water; the suspending agent is a mixture of xanthan gum and locust bean gum. The potassium ion exchange capacity of the sodium zirconium cyclosilicate oral suspension of the present invention is equivalent to that of the commercially available powder and has good dispersion stability.

The invention belongs to the technical field of pharmaceutical preparations, and relates to an anhydroicaritin nanocrystal oral suspension and a preparation method thereof. The oral suspension contains anhydroicaritin nanocrystals, a suspending aid, a surfactant, a buffer salt system and other pharmaceutically acceptable auxiliary materials. By optimizing the surfactant system and the pH range, the stability of the anhydroicaritin is effectively improved. The problem of long-term stability of a nanocrystalline oral suspension preparation prepared from anhydroicaritin is solved. According to the prescription, the dissolution speed of the medicine is increased, the bioavailability is improved, and the preparation method is easy to operate, stable in process and suitable for industrial production.

This document discloses rivaroxaban tablets for oral suspension formulation for oral administration. Also disclosed is a method for preparing rivaroxaban tablets for oral suspension and a method of treating diseases.

An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg / mL for the treatment of attention-deficit / hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg / mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence. The invention further provides scalable manufacturing methods, quality control specifications, and methods of use for treating ADHD, offering a stable, safe, and patient-friendly alternative to solid oral dosage forms.

The present application belongs to the technical field of pharmaceutical analysis, and particularly relates to a kind of analytical method for determining genetic toxic impurities in nilotinib composition.The present application has good specificity, simple operation, high sensitivity, low cost, and is suitable for frequent detection in mass production, etc., for determining impurity A in compositions such as nilotinib oral suspension, nilotinib dry suspension or nilotinib capsules.The method can effectively separate the nilotinib impurity A peak from its adjacent impurity peak, and solve the problem of easy damage of the chromatographic column during the determination of nilotinib impurity A.

This invention discloses an oral suspension of an anti-tuberculosis drug and its preparation method. The oral suspension contains an anti-tuberculosis drug, a suspending agent, a surfactant, an antibacterial agent, an antioxidant, a flavoring agent, and a pH adjuster. It has technical advantages such as stable physical and chemical properties, uniform content, and easy long-term storage.

The invention discloses a stable eplerenone oral suspension and a preparation method thereof. According to the oral suspension, a buffer pair pH regulator is adopted to regulate the pH value of the oral suspension of the system to 3.0-5.0, so that the stability of the product in the storage process is maintained. Meanwhile, compared with eplerenone tablets, the eplerenone oral suspension provided by the invention has the advantages that the absorption is faster, the in-vivo exposure of the medicine is larger, the bioavailability is obviously improved by about 50%, and a reliable high-stability and high-bioavailability eplerenone oral suspension preparation scheme is provided clinically.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a solifenacin succinate taste-masking composition and a preparation method thereof. Comprising solifenacin succinate and an auxiliary material for preparing the oral suspension, the auxiliary material comprises polacrilin potassium, and the mass ratio of solifenacin succinate to polacrilin potassium is (0.5-2): (1-4); the particle size condition of the polacrilin potassium is as follows: D90 is 110-180 [mu] m, and D50 is 30-80 [mu] m. The solifenacin succinate taste-masking composition provided by the invention not only has a good taste-masking effect, but also can improve the dissolution curve of solifenacin succinate, so that the medication compliance of a patient is improved, side effects are reduced, and the curative effect of solifenacin succinate is further ensured.

The present invention relates to a pharmaceutical composition comprising ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizers in the form: A) an aqueous solution for intravenous administration comprising a sodium salt or lysine salt of ibuprofen, acetaminophen and preferably one or more cyclodextrins; or B) an aqueous solution for intravenous administration wherein the one or more solubilizing agents are one or more essential amino acids and optionally one or more cyclodextrins; or C) a composition for oral administration comprising acetaminophen and cyclodextrin wherein the composition is in the form of i) an effervescent tablet or effervescent granule, or ii) an oral suspension or syrup or oral solution, or iii) a soft capsule.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to anhydroicaritin nanocrystalline oral suspension and a preparation method thereof. The oral suspension disclosed by the invention contains anhydroicaritin nanocrystals, a space protecting agent, a surfactant, a preservative, a pH regulator and other pharmaceutically acceptable auxiliary materials. Compared with the prior art, the problem that the stability is poor after the anhydroicaritin is prepared into the nanocrystal is solved; particle size distribution is uniform, and aggregation and layering phenomena are avoided; related substances are controllable, the safety is higher, the taste is good, the dosage can be accurately divided according to the body weight, and children, old people and patients with dysphagia can take the medicine conveniently. The oral suspension is simple in preparation method and suitable for industrial production.

The invention discloses a lamotrigine oral suspension and a preparation method thereof, the lamotrigine oral suspension is composed of lamotrigine and other pharmaceutic adjuvants, the pharmaceutic adjuvants are composed of a suspending aid, a wetting agent, a bacteriostatic agent, a flavoring agent, a defoaming agent, a pH regulator and a solvent, and the wetting agent is hydroxypropyl methylcellulose, glycerin, Tween 80 and the like. According to the invention, the suspending aid is adopted to increase the liquid viscosity and improve the stability of the suspension, and the wetting agent is adopted to improve the hydrophobicity of API, so that the stability and redispersibility of the suspension are improved, and the preparation process is simple and suitable for industrial mass production.

The invention relates to the technical field of medical medicines, in particular to a taste-masking oral suspension containing 3-boryl-L-phenylalanine and a preparation method of the taste-masking oral suspension. Each 100 mL of the taste-masking oral suspension is prepared from the following components: 4 to 6 g of 3-boryl-L-phenylalanine, 8.5 to 17.5 g of beta-cyclodextrin, 0.08 to 0.12 g of stevioside, 0.03 to 0.08 g of lemon essence, 0.25 to 0.35 g of xanthan gum and 0.08 to 0.12 g of potassium sorbate. On the basis of an intermolecular hydrophobic interaction principle, a benzene ring bitter group of 3-BPA is specifically included by utilizing a hydrophobic cavity of beta-cyclodextrin, so that taste perception is reduced; natural stevioside (free of heat and dental caries risk) and lemon essence (capable of covering residual peculiar smell) form a synergistic taste-masking system, and the synergistic taste-masking system is matched with a xanthan gum suspending aid to prepare a uniform suspension; the preparation has the core advantages that the characteristic of high water solubility (125 g / L) of 3-BPA is fully utilized, the preparation does not need to add any solubilizer, taste optimization, stability improvement and swallowing convenience adaptation are synchronously realized, and three core requirements of'curative effect, safety and compliance 'of medication for children are considered.

The invention relates to the technical field of medical auxiliary equipment, and discloses a medicine concentration adjustable quantitative proportioning device for oral suspension for children, which comprises a base, a shell, a suspension conveying mechanism, a solvent conveying mechanism and a stirring mechanism, a blending cup is mounted on the base, and a weighing sensor is mounted between the bottom of the blending cup and the base; the shell is detachably installed on the base and can seal the open end of the blending cup, a suspension storage tank and a solvent storage tank are installed in the shell, and a discharging port and a liquid outlet are formed in the bottom side of the shell; the suspension conveying mechanism is used for conveying the suspension in the suspension storage tank into the blending cup; and the solvent conveying mechanism is used for conveying the solvent in the solvent storage tank to the blending cup. By means of the device, a user can conveniently and automatically prepare suspensions of any concentration according to actual conditions, the risk that the suspensions, solvents and mixed liquid interfere with one another can be reduced, meanwhile, the device can be controlled through voice, and convenience is high.

This document discloses rivaroxaban tablets for oral suspension formulation for oral administration. Also disclosed is a method for preparing rivaroxaban tablets for oral suspension and a method of treating diseases.

The invention relates to the field of pharmaceutical preparations, in particular to a fexofenadine hydrochloride oral suspension and a preparation method thereof. The invention relates to a fexofenadine hydrochloride oral suspension, which is composed of the following components by weight / volume (g / 100mL): 0.6% of fexofenadine hydrochloride; 0.5%-1.0% of a suspending aid; 0.02% to 0.08% of a wetting agent; the suspending aid is a combination of hydroxyethyl cellulose, xanthan gum and microcrystalline cellulose-sodium carboxymethyl cellulose, the pH value of the buffering agent is adjusted to 5.8-7.0, and the suspending aid is a combination of hydroxyethyl cellulose, xanthan gum and microcrystalline cellulose-sodium carboxymethyl cellulose; the preparation process of the fexofenadine hydrochloride oral suspension comprises the step of autoclaving. The fexofenadine hydrochloride oral suspension disclosed by the invention does not contain a bacteriostatic agent, a bacteriostatic agent cosolvent, an opacifying agent and essence, is simple in component and high in safety, and has great clinical advantages.

The invention discloses a fumaric acid Vonoprazan suspension and a preparation method thereof, the fumaric acid Vonoprazan suspension is prepared from fumaric acid Vonoprazan, a suspending aid, a wetting agent, an acidifying agent, a flavoring agent and essence, the prepared preparation is easier to swallow compared with tablets, proper auxiliary materials are screened and added through a prescription, the bitter taste of the fumaric acid Vonoprazan during oral administration is obviously reduced, and the oral administration effect of the fumaric acid Vonoprazan is improved. The clinical compliance of a patient is improved; and the defects that the tablet is taken after being broken apart, the dosage is not accurate enough, the coating is damaged and the taste masking effect is influenced are overcome. The oral suspension is packaged in unit dose, and is accurate in dose and convenient to administrate.

The invention relates to the technical field of medicaments, and discloses a medicament and a method for relieving inflammatory response of chronic nephropathy by a composition for regulating intestinal flora, the medicament takes'probiotics, prebiotics and postbiotics' as a core, the probiotics contain bifidobacterium lactis and Akk bacteria, the prebiotics are fructo-oligosaccharide-inulin mixture, the postbiotics are butyrin, and the prebiotics and the postbiotics are mixed uniformly. Astragalus polysaccharide / lycium barbarum polysaccharide can be added for synergistic interaction; dosage forms of the enteric capsule, the powder and the oral suspension are divided into enteric capsules, powder and oral suspension, the enteric capsule is suitable for different people groups, inflammation is relieved by repairing intestinal barriers, inhibiting NF-kB channels and optimizing flora, after 12-24 weeks of administration, serum IL-6, TNF-alpha and hs-CRP are reduced by 15%-55%, renal functions and cardiovascular complications are synchronously improved, the enteric capsule is free of kidney toxicity, the adverse reaction rate is smaller than or equal to 5%, and the enteric capsule is suitable for long-term intervention of CKD inflammation.

The invention provides a stable perampanel oral suspension and a preparation method thereof, the oral suspension adopts carboxylated nanocellulose (CNF) as a suspending aid and octadecanol as a defoaming agent, and adopts a high-shear dispersion mode in the preparation process, so that the stability, uniformity, suspension effect and dissolution rate of active ingredients in the suspension can be effectively improved, and the stability, the uniformity, the suspension effect and the dissolution rate of the perampanel oral suspension are improved. The pharmaceutical composition has the advantages of being good in suspension effect, high in content uniformity, high in dissolution speed, low in content of related substances, good in stability, high in bioavailability, convenient to take, capable of improving patient compliance and the like, and the preparation method is simple, high in operability and suitable for large-scale industrial production.

The invention discloses a preparation method of an atorvastatin calcium oral suspension, and belongs to the technical field of pharmaceutical preparations. The preparation method provided by the invention comprises the following steps: adding part of water into a liquid preparation container, heating and carrying out nitrogen filling treatment, then adding a preservative and part of a suspending aid, and stirring to obtain first liquid; the suspending aid comprises Arabic gum; adding a part of water into another container, carrying out nitrogen charging treatment, then adding the remaining suspending aid and atorvastatin calcium, carrying out shearing dispersion, then mixing with the second liquid, then adding a flavoring agent and the remaining water, carrying out volume metering and nitrogen charging, and controlling the dissolved oxygen content to be less than 3mg / L; and filling into a bottle purged by nitrogen, carrying out headspace nitrogen charging after the filling is finished, so that the residual oxygen content in the bottle is below 5%, and sealing a cover. According to the invention, the physical stability and chemical stability of the atorvastatin calcium oral suspension are remarkably improved, and meanwhile, compared with the existing dosage form, the dosage form of the obtained oral suspension has better patient compliance and flexibility.

The present invention relates to a pharmaceutical composition, advantageously a ready-to-use liquid composition or a dry powder for redissolution, comprising: sinocarbamate or a salt, hydrate or solvate thereof, where the pharmaceutical composition for administration is preferably an oral suspension; a kit for precise metering and administration of pharmaceutical compositions. In addition, the present composition has at least one surface modifier for controlling the solid state of the sinocarbamate in the suspension; and a method for treating focal seizures in a human patient comprising administering a therapeutically effective amount of the pharmaceutical composition.

This invention discloses a perampanel oral suspension and its preparation method. The preparation method of this invention includes the following steps: S1, adding microcrystalline cellulose sodium carboxymethyl cellulose co-treatment material to water for homogenization to obtain a first dispersion; S2, adding sorbitol, an antibacterial agent, and a pH adjuster to the first dispersion to obtain a second dispersion; S3, pulverizing perampanel and sieving it to control the particle size D. 90 The sample size is 10–15 μm; S4, the perampanel obtained in step S3 is subjected to antistatic treatment; S5, the perampanel treated in step S4, defoamer, and polyoxyethylene hydrogenated castor oil are added to the second dispersion to obtain the third dispersion; S6, water is added to the third dispersion to bring it to a final volume, and homogenization is performed to obtain the perampanel oral suspension. This method can significantly improve the dissolution rate, long-term stability, and control level of drug-related substances at day 0, and improve the uniformity of content.